A sudden, rapid heart rate will send many to the emergency room. Every year, more than 140,000 emergency room visits are related to a specific type of increased heart rate called paroxysmal ...

CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular tachycardia to normal sinus rhythm with a significant reduction in ED utilization and ...

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST), a clinical-stage biopharmaceutical company focused on cardiovascular medicines, announced Monday positive results from Phase 3 RAPID clinical trial ...

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

Photo Credit: AHA/Scott Morgan 2022. Used with permission. CHICAGO, IL—Full results of the RAPID trial testing etripamil nasal spray for patients with paroxysmal supraventricular tachycardia (PSVT) ...

Etripamil is a calcium channel blocker designed to be administered intranasally to treat episodes of PSVT in an at-home setting. The Food and Drug Administration (FDA) has accepted for review the New ...

Etripamil is a self-administered nasal spray designed to be a rapid-response therapy for episodic cardiovascular conditions. Positive topline data were announced from a phase 3 trial evaluating the ...

A New Drug Application (NDA) for CARDAMYST is currently being evaluated by the U.S. Food & Drug Administration (FDA) which has set a new Prescription Drug User Fee Act (PDFUA) target date of December ...

Self-administered intranasal etripamil was nearly twice as likely as placebo to terminate a paroxysmal supraventricular tachycardia (PSVT) episode within 30 minutes and reduced emergency department ...

MONTREAL and CHARLOTTE, N.C., Nov. 15, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. MIST, a biopharmaceutical company focused on the development and commercialization of innovative ...

There was no revenue recorded for the fourth quarter or full year ended December 31, 2024, compared to $1.0 million in 2023, indicating potential challenges in generating income. The company reported ...